immuno-oncology companies

Companies whose enriched business profile is tagged “immuno-oncology”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + market data, shown with its as-of date.

• CG ONCOLOGY INC (CGON) Health Care — CG Oncology is an immuno-oncology company developing bladder-sparing therapeutics for patients with non-muscle invasive bladder cancer. ask →
• PRECIGEN INC (PGEN) Health Care — A commercial-stage precision medicine company leveraging proprietary adenoviral and CAR-T platforms to address intractable diseases, notably including the FDA-approved RRP therapy Papzimeos. ask →
• JANUX THERAPEUTICS INC (JANX) Health Care — Janux Therapeutics is a clinical-stage biotech developing tumor-activated T-cell engagers and immunomodulators to treat cancer and autoimmune diseases with reduced toxicity. ask →
• CRESCENT BIOPHARMA INC (CBIO) Health Care — A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors. ask →
• ARVINAS INC (ARVN) Health Care — Arvinas is a pioneer in the field of targeted protein degradation, leveraging its PROTAC platform to develop a new class of medicines for complex oncology and neurology diseases. ask →
• ALLOGENE THERAPEUTICS INC (ALLO) Health Care — Allogene Therapeutics is pioneering off-the-shelf, allogeneic CAR T cell therapies to provide faster, more scalable treatment options for cancer and autoimmune patients compared to traditional autologous approaches. ask →
• AGENUS INC (AGEN) Health Care — Agenus is a biotechnology company advancing a novel, multifunctional immunotherapy combination for difficult-to-treat cancers like MSS colorectal cancer. ask →
• TRISALUS LF SC CM A (TLSI) Health Care — TriSalus combines a proprietary pressure-enabled drug delivery (PEDD) platform with immunotherapy to overcome physical and biological barriers in treating solid tumors. ask →
• GALECTIN THERAPEUTICS INC (GALT) Health Care — A clinical-stage biopharmaceutical company developing novel carbohydrate-based galectin-3 inhibitors to address advanced liver fibrosis and MASH cirrhosis. ask →
• COHERUS ONCOLOGY INC (CHRS) Health Care — A specialized immuno-oncology company driving growth through its FDA-approved PD-1 inhibitor LOQTORZI and a clinical-stage pipeline targeting immune resistance in solid tumors. ask →
• ALX ONCOLOGY HOLDINGS INC (ALXO) Health Care — ALX Oncology is a clinical-stage biotech company developing a pipeline of innovative cancer therapies, including a next-generation CD47-blocking checkpoint inhibitor and a novel EGFR-targeted antibody-drug conjugate. ask →

Not quite it? Describe exactly what you want →

Data: SEC EDGAR (filings) + market data (fundamentals, delayed daily-close). Figures shown with their as-of date.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.